Drug Profile
Research programme: trastuzumab biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Alternative Names: Anti-HER2/neu mAb biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical; Fderceptin; Herceptin biosimilar - Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLatest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Breast-cancer in China (Parenteral)
- 06 May 2015 Preclinical trials in Breast cancer in China (Parenteral), before May 2015